Stephens raises target for Pacific Biosciences stock to USD 2.50
Published on 10/24/2026 at 18:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and earnings date
- Stephens raised its Pacific Biosciences target from USD 1.50 to USD 2.50 on October 23, 2026.
- PacBio is scheduled to report third-quarter 2026 results on November 4, 2026.
- Pacific Biosciences stock costs EUR 1.87 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
- Second-quarter revenue was USD 39.01 million against a USD 42.90 million consensus estimate.
Stephens raised its price target for Pacific Biosciences (ISIN US69404D1081) to USD 2.50 from USD 1.50 on October 23, 2026, while maintaining an Overweight rating, according to Markets Insider. Pacific Biosciences stock was trading at EUR 1.87 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
November 4 sets the next test
PacBio is scheduled to report its third-quarter 2026 financial results on November 4, 2026. The company listed the reporting date and conference call on its investor-relations page, Pacific Biosciences.
Stock stays inside a wide range
Pacific Biosciences closed at USD 2.11 on Nasdaq on October 23, 2026 at 4:00 p.m. ET. Its 52-week range was USD 1.07 to USD 3.43, while market capitalization stood at USD 655.9 million and volume reached 5.71 million shares. The company operates in healthcare and develops long-read and short-read genetic sequencing systems, consumables and related software.
What does the target change mean?
The Stephens revision puts the new USD 2.50 target USD 1.00 above its previous USD 1.50 level. A separate MarketBeat survey placed the average target at USD 1.71 and the consensus rating at Reduce, based on six analysts, as reported on October 23, 2026 by MarketBeat.
PacBio's second-quarter 2026 revenue was USD 39.01 million, compared with a USD 42.90 million consensus estimate. For the third quarter, analysts estimated revenue of USD 41.193 million and adjusted earnings per share of minus USD 0.15, according to ChartMill.
Comparison with peers
Pacific Biosciences: price-to-earnings ratio minus 4.91, market capitalization USD 655.9 million.
Illumina (Nasdaq, USD): price-to-earnings ratio 50.26, market capitalization USD 40.7 billion.
CRISPR Therapeutics (Nasdaq, USD): price-to-earnings ratio minus 10.38, market capitalization USD 4.8 billion.
Targets and results frame the stock
The revised Stephens target and the November reporting date give investors two concrete reference points. The next report will show whether PacBio's revenue trajectory is moving closer to the USD 41.193 million third-quarter consensus.
The further course of trading is shown by the continuously updated real-time quote of Pacific Biosciences stock.
Pacific Biosciences stock at a glance
- Company: Pacific Biosciences of California, Inc.
- ISIN: US69404D1081
- Ticker: PACB
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 24, 2026, 1:04 p.m. CEST): EUR 1.87
- Market capitalization: USD 655.9 million (as of October 23, 2026)
- 52-week range: USD 1.07-USD 3.43 (as of October 23, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P 500.
